--- title: "SYNEDGEN, INC. — Capability Statement" uei: "HX79BD6YQ521" cage: "5JGC8" canonical: "https://teamingindex.com/contractor/HX79BD6YQ521/capability.md" html_url: "https://teamingindex.com/contractor/HX79BD6YQ521" updated: "2026-11-09T17:28:18.052Z" generator: "TeamingIndex capability twin 1.0" legal_name: "SYNEDGEN, INC." dba_name: "SYNEDGEN INC" primary_naics: "541715" sam_status: "expired" active_exclusion: false claimed: false tier: "unclaimed" --- # SYNEDGEN, INC. > SYNEDGEN, INC. (DBA SYNEDGEN INC) is a SAM.gov-registered entity based in CLAREMONT, CA 91711-3583. UEI HX79BD6YQ521; CAGE 5JGC8; primary NAICS 541715. Compliance posture not provided. SAM registration expired. > **Notice: SAM registration expired.** An active SAM registration is generally required when an offer is submitted and at award (FAR 4.1102). > **Unclaimed profile:** seeded from SAM.gov and USAspending public records. The entity has not claimed it, so capabilities and compliance posture have not been provided. ## Identifiers - **Legal business name:** SYNEDGEN, INC. - **DBA name:** SYNEDGEN INC - **UEI (SAM.gov Unique Entity ID):** HX79BD6YQ521 - **CAGE code:** 5JGC8 - **Entity structure:** Corporate Entity (Not Tax Exempt) - **State of incorporation:** DE - **Website:** - **TeamingIndex profile:** - **Profile status:** Unclaimed · seeded from SAM.gov and USAspending public records ## Location - **Physical address (city, state, ZIP):** CLAREMONT, CA 91711-3583 - **Country:** United States - **Congressional district:** CA-28 ## NAICS & PSC | NAICS | Title | Primary | Small under SBA size standard (SAM.gov) | | --- | --- | --- | --- | | 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | Yes | No | - **PSC codes:** None on file Size status is NAICS-specific and reflects the entity’s SAM.gov representations; check it against the size standard of the solicitation’s NAICS code. ## Socio-economic status No socio-economic designations reported in SAM.gov. Source: SAM.gov entity registration, synced 2026-11-09. Confirm current SBA certification (8(a), HUBZone, WOSB/EDWOSB, VetCert SDVOSB/VOSB) before relying on a status for a set-aside. ## SAM registration & exclusion screening - **Registration:** SAM registration expired - **Registration expires:** 2026-11-11 - **Registration activated:** 2025-11-13 - **Exclusion screening (FAR subpart 9.4):** No active exclusion recorded in SAM.gov - **Teaming eligibility:** Not eligible to be proposed as a team member until the SAM registration is active - **Source:** SAM.gov Entity Management, synced 2026-11-09 ## Compliance posture Compliance posture not provided by the contractor. - Facility clearance: visible to paid members - Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). ## Contract vehicles No contract vehicle holdings on file. ## Past performance - **Total obligated, trailing 36 months (USAspending.gov):** $21,126,078 - **Award history:** 2 awards on record - **Top funding agencies:** Office of Assistant Secretary for Preparedness and Response; Defense Health Agency Showing all 2 awards. | Award PIID | Agency | NAICS / PSC | Obligated | Base + all options | Period of performance | Set-aside | Place of performance | Description | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 75A50124C00047 | Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response | 541715 / AN13 | $18,828,663 | — | 2024-09-30 → 2027-05-31 | — | CA | ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE… | | HT942524C0049 | Department of Defense / Defense Health Agency | 541715 / AN12 | $2,297,415 | — | 2024-09-20 → 2026-09-19 | — | CA | SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION… | ## Proven teaming graph - No first-tier sub-award reports name this company yet - Source: USAspending.gov sub-award reports (FSRS), sync date not recorded. Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values. ## SBIR/STTR portfolio - SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects - 10 SBIR/STTR awards totaling $4.9M: SBIR Phase I 7, SBIR Phase II 3 - By agency: Department of Health and Human Services 7, Department of Defense 3 - SBIR Phase II, Department of Defense (Defense Health Agency), 2020, Mar 2, 2020 to Jul 1, 2021: Development of Technologies that Control Scar Formation after Burn Injuries ($1,000,000) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2016, May 1, 2016 to Apr 30, 2017: Novel treatment for Crohn's disease and related inflammatory gastrointestinal disease ($224,412) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2015, Aug 1, 2015 to Feb 28, 2017: Prevention and treatment of GI obstruction syndromes in cystic fibrosis ($146,412) - SBIR Phase II, Department of Defense (Defense Health Agency), 2014, Sep 26, 2014 to Feb 25, 2016: Effective New Topical Treatment to Reduce Scar Formation in Burns ($870,530) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2014: Clinical Development of IPdR for Radiosensitization Period of Performance: 09/19/2014 - 06/18/2015 ($196,707) - SBIR Phase I, Department of Defense (Defense Health Agency), 2013, May 30, 2013 to Dec 31, 2013: Effective New Topical Treatment to Reduce Scar Formation in Burns ($149,904) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2013: Rectal Medication Administration Device for Palliative Care ($149,901) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2011: Antimicrobial and Regenerative Treatment for Oral Mucositis ($1,963,826) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2010: Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba ($99,638) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2009: Prevention and Treatment of Oral Biofilms and Related Oral Disease by Soluble Chi ($99,665) - Phase III: Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual. - Source: SBIR.gov award data file, as of Nov 12, 2026 (file published Nov 1, 2026) ## FedRAMP offerings - No FedRAMP Marketplace listing is linked to this company - Source: FedRAMP Marketplace, sync date not recorded ## Exclusions & screening - No active SAM.gov exclusion on record (checked Nov 14, 2026) - Source: SAM.gov Exclusions, as of Nov 14, 2026 - No confirmed match on the Consolidated Screening List (screened Nov 14, 2026) ## Contract vehicles on federal record - No contract-vehicle seats on federal record are linked to this company ## GSA CALC+ rates - No GSA CALC+ awarded ceiling rates on record for this company - Source: GSA CALC+ awarded ceiling rates, sync date not recorded. Ceiling rates are the most an agency can be charged, not prices paid ## Capabilities & differentiators No capability narrative published. ## Technical tags No technical tags published. ## Teaming preferences - Teaming preferences not published - **Teaming requests and NDAs:** request an introduction on the TeamingIndex profile (sign-in required): ## Business development contact No business-development contact published. ## Corporate hierarchy - No parent entity reported in SAM.gov - Affiliation with a parent or sister concerns can affect small-business size status (13 CFR 121.103). ## Provenance & disclaimer - **SAM.gov entity registration** (identifiers, NAICS/PSC, size and socio-economic status, hierarchy, registration and exclusion status): synced 2026-11-09 - **USAspending.gov** (prime award history and trailing 36-month obligations): nightly sync - **Contractor-provided profile** (capabilities, teaming preferences, self-attested compliance): not provided - **TeamingIndex verification** (credentials marked “Verified by TeamingIndex”): no verified credentials on record; methodology: - **Blind SPRS:** exact NIST SP 800-171 SPRS scores are published only when the contractor opts in; brackets are cumulative thresholds (SPRS ≥ 0, SPRS ≥ 50, SPRS ≥ 70, SPRS ≥ 85, SPRS ≥ 95, SPRS ≥ 105, SPRS = 110 (perfect)). - **Before award:** self-attested facts have not been independently verified. Confirm registration and exclusions in SAM.gov, CMMC status and SPRS assessment currency with the contractor (DFARS 252.204-7019, -7020 and -7021), facility clearances through DCSA’s NISS, AS9100-series certificates in the IAQG OASIS database, and FedRAMP authorizations on the FedRAMP Marketplace. - **Zero CUI:** this document contains no Controlled Unclassified Information. TeamingIndex stores verification metadata only, never SSPs, POA&Ms or DD Form 254s. - **Machine-readable:** schema.org JSON-LD is embedded in ; this twin: ; site index: © 2026 HILARTECH, LLC. All rights reserved. TeamingIndex.com is an independent defense industrial base intelligence platform owned and operated by HILARTECH, LLC and is not affiliated with or endorsed by the U.S. Department of Defense (DoD), the General Services Administration (GSA), or SAM.gov.